Investigating HDR Brachytherapy for Prostate Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational trial focuses on patients with localized prostate cancer who are suitable for High Dose Rate (HDR) brachytherapy as a standalone treatment. Utilizing a multi-omics approach, the study aims to explore the mechanisms of HDR brachytherapy through various profiling techniques, including metabolomics, immunological assessments, transcriptomics, and spectroscopic analysis. The research will document the dose-response relationship of HDR brachytherapy by measuring changes in tumor metabolites and evaluating immune responses before and after treatment. The goal is to clarify the optimal dosing for HDR brachytherapy and its immunogenic effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.
* Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8
* ECOG 0-1
* Low tier intermediate-risk prostate cancer is defined by: a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA \< 10 ng/ml OR Gleason 6 and PSA 10-20 ng/ml)
* Extensive favorable-risk disease is defined as: clinical stage T1c-T2a, PSA \< 10, Gleason 6, ≥ 50% of biopsy cores containing cancer, PSA density \> 0.2 ng/cc,
* Selected intermediate risk patients not defined above

  * T1c/T2a
  * PSA \< 10 and Gleason 4+3
  * PSA \> 10 (\< 20) and Gleason 3+4
  * PSA 10-15 ng/ml and Gleason 4+3 and \< 33% cores involved
  * Max tumor length in any core 10 mm
* No androgen deprivation therapy (ADT)
* Signed study specific informed consent.

Exclusion Criteria:

* Prior radical surgery for carcinoma of the prostate,
* Prior pelvic radiation
* Prior chemotherapy for prostate cancer,
* Claustrophobic or unable to undergo MRI
* Patients unsuitable for general anesthesia, on blood thinners which cannot be stopped for 24 hours, or who have contraindications to radiotherapy such as systemic sclerosis, or inflammatory bowel disease

Where it's running

• British Columbia Cancer Center for the Southern Interior
  Kelowna, British Columbia, Canada Recruiting

Study contacts

• Principal investigator: Juanita M Crook, MD — Radiation Oncologist
• Study coordinator: Juanita M Crook, MD
• Email: jcrook@bccancer.bc.ca
• Phone: 250 712 3958

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exercise after pelvic radiation to see if it lowers colorectal cancer risk

  This study tests whether regular walking therapy after pelvic radiation for prostate cancer can influence markers of colorectal cancer in colon tissue and blood.

  Recruiting at 2 sites City of Hope Medical Center · Duarte, California and 1 other locations · NCT07790718

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• MRI-based microboost SBRT with de-escalated whole-gland radiation for localized prostate cancer

  This study tests whether giving a focused 45 Gy microboost to MRI-defined lesions with smaller whole-gland doses (30 or 35 Gy) is safe and effective for men with low- to intermediate-risk localized prostate cancer.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia · NCT07644598

• Short-term hormone therapy with PSMA PET/CT before prostate removal for high-risk localized prostate cancer

  This trial will test whether giving short-term androgen-deprivation therapy (ADT) before prostate removal lowers PSMA PET signal and helps predict recurrence risk in men with localized high-risk prostate cancer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT07455903

• Comparing Lutetium-177 and Actinium-225 PSMA-targeted radiation before prostatectomy

  This will test whether giving one of two PSMA-targeted radiation drugs (Lutetium-177 or Actinium-225) before prostate removal works differently in men with high or very high-risk localized prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07054346

• Wrapping nerves with a multi-layer perinatal tissue graft during prostate removal

  This trial will test whether wrapping the nerves with a multi-layer perinatal tissue allograft during nerve-sparing robotic prostate removal helps men with localized prostate cancer keep erectile and urinary function.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06940271

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.